News
Press Releases
BlueRock Therapeutics receives FDA Fast Track Designation for OpCT-001 for the treatment of primary photoreceptor diseases
February 27, 2025Press Releases
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial
January 13, 2025Research Insights
How new modalities could evolve the treatment of Parkinson’s disease
November 13, 2024Research Insights
Cell Therapy and Vision Loss: A Primer on Primary Photoreceptor Diseases
November 13, 2024Research Insights
A Strategy to Compare Single-Cell RNA Sequencing Data Sets Provides Phenotypic Insight into Cellular Heterogeneity Underlying Biological Similarities and Differences Between Samples
October 8, 2024Research Insights
Retinitis Pigmentosa in Perspective: An Interview with Charles-Edouard Catherine
October 2, 2024Press Releases
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
September 27, 2024Research Insights
Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses
September 17, 2024Press Releases
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases
September 3, 2024Press Releases
